**Central Nervous System (CNS) Agents: Sedative-Hypnotics,
Non-Barbiturate** 

| Criteria 1 | NP Criteria- Controlled Medications – Belsomra, Dayvigo, Eszopiclone, Intermezzo, Quviviq, Temazepam 7.5, Temazepam 22mg, Zolpidem ER, Zolpidem SL |
| ---------- | -------------------------------------------------------------------------------------------------------------------------------------------------- |
| Criteria 2 | NP Criteria- Non-Controlled Medications – Doxepin 3mg, Doxepin 6mg, Ramelteon                                                                      |

    

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Central Nervous System (CNS) Agents: Sedative-Hypnotics, Non-Barbiturate</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred Products: Controlled</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>BELSOMRA</td>
<td>072690</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>BELSOMRA</td>
<td>072691</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>BELSOMRA</td>
<td>072692</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>BELSOMRA</td>
<td>072693</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>DAYVIGO</td>
<td>080590</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>DAYVIGO</td>
<td>080591</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ESZOPICLONE</td>
<td>058482</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ESZOPICLONE</td>
<td>058483</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ESZOPICLONE</td>
<td>058484</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>INTERMEZZO</td>
<td>068726</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>INTERMEZZO</td>
<td>068727</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>QUVIVIQ</td>
<td>082964</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>QUVIVIQ</td>
<td>082965</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TEMAZEPAM 7.5 and 22 mg</td>
<td>019182</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>TEMAZEPAM 7.5 and 22 mg</td>
<td>058570</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ZOLPIDEM ER, SL</td>
<td>059696</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ZOLPIDEM ER, SL</td>
<td>059697</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ZOLPIDEM ER, SL</td>
<td>065334</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ZOLPIDEM ER, SL</td>
<td>065335</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">10 days</span> with at least <span class="underline">two preferred</span> drugs?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</p>
<p> </p></td>
<td> Y    </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>8</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>9</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 180 Days  

| **Last Approved ** | 4/24/2023 |
| ------------------ | --------- |
| **Other**          |           |

**  
**

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Central Nervous System (CNS) Agents: Sedative-Hypnotics, Non-Barbiturate</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred Products: Non-Controlled</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>DOXEPIN 3 mg and 6 mg</td>
<td>066591</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>DOXEPIN 3 mg and 6 mg</td>
<td>066592</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>RAMELTEON</td>
<td>059509</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>0997</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0998</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0998</td>
<td></td>
<td> Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y  </td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>3</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Does the patient have a history of addiction?</td>
<td>Y </td>
<td>END (Approve x 180 days)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1000</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">10 days</span> with at least <span class="underline">two preferred</span> drugs?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>6</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Approve x 180 days)</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Approve x 180 days)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</p>
<p> </p></td>
<td> Y    </td>
<td>END (Approve x 180 days)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>9</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>10</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 180 days  

| **Last Approved ** | 4/24/2023 |
| ------------------ | --------- |
| **Other**          |           |
